Seasonal Vaccines Market Accelerating Growth and Rising Opportunities Through 2035

The seasonal vaccines market is entering a strong growth phase, projected to generate substantial revenues between 2025 and ...

Gilead Sciences, Inc. (GILD) Presents at Evercore 8th Annual Healthcare Conference Transcript

Evercore 8th Annual Healthcare Conference December 3, 2025 10:50 AM ESTCompany ParticipantsDietmar Berger - Chief ...
The American Journal of Managed Care

Experts Say FDA Approval of Perioperative Durvalumab Plus FLOT Sets New Standard of Care for Early-Stage Gastric, GEJ Cancers

As the first immunotherapy option in this setting, the approval sets a new standard for resectable early-stage gastric and gastroesophageal junction (GEJ) cancers.

Sagent Launches Bludigo(R), an Indigo Carmine Injection, Through New Partnership with Provepharm

Sagent Pharmaceuticals ("Sagent"), a leading provider of injectables to the U.S. market, is excited to announce a strategic partnership with Provepharm to commercialize three innovative diagnostic ...

FDA approves Imfinzi for early gastric and gastroesophageal cancers

The U.S. Food and Drug Administration has approved Imfinzi (durvalumab) in combination with standard-of-care FLOT ...
Precision Medicine Online

Imvax to Discuss Phase II Data of IGV-001 in Glioblastoma With FDA

The firm said treatment with the autologous immunotherapy demonstrated increased overall survival compared to placebo in a Phase II study.